Mannkind (MNKD) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.87% |
| Dec 31, 2025 | -104.61% |
| Sep 30, 2025 | 30.30% |
| Jun 30, 2025 | 34.67% |
| Mar 31, 2025 | 10.68% |
| Dec 31, 2024 | 45.11% |
| Sep 30, 2024 | 16.86% |
| Jun 30, 2024 | 17.02% |
| Mar 31, 2024 | 20.85% |
| Dec 31, 2023 | -2.80% |
| Sep 30, 2023 | 21.27% |
| Jun 30, 2023 | 15.95% |
| Mar 31, 2023 | 15.48% |
| Dec 31, 2022 | 39.77% |
| Sep 30, 2022 | -3.82% |
| Jun 30, 2022 | -9.81% |
| Mar 31, 2022 | -32.89% |
| Dec 31, 2021 | 0.64% |
| Sep 30, 2021 | 8.03% |
| Jun 30, 2021 | -13.26% |
| Mar 31, 2021 | 16.17% |
| Dec 31, 2020 | 14.99% |
| Sep 30, 2020 | 7.51% |
| Jun 30, 2020 | 27.03% |
| Mar 31, 2020 | -41.71% |
| Dec 31, 2019 | 32.24% |
| Sep 30, 2019 | -20.30% |
| Jun 30, 2019 | 3.37% |
| Mar 31, 2019 | 20.70% |
| Dec 31, 2018 | 22.28% |
| Sep 30, 2018 | 15.81% |
| Jun 30, 2018 | 1.81% |
| Mar 31, 2018 | 7.53% |
| Dec 31, 2017 | -1.31% |
| Sep 30, 2017 | 7.44% |
| Jun 30, 2017 | 4.35% |
| Mar 31, 2017 | 17.73% |
| Dec 31, 2016 | 8.93% |
| Sep 30, 2016 | 8.53% |
| Jun 30, 2016 | 20.72% |
| Mar 31, 2016 | -0.04% |
| Dec 31, 2015 | 10.36% |
| Sep 30, 2015 | 10.61% |